Showing 1691-1700 of 10817 results for "".
Weighing the Prospects of Biosimilars
https://practicaldermatology.com/columns/clinical-focus-1/weighing-the-prospects-of-biosimilars/21477/If they are found to be comparable to the “originators,” biosimilar agents may offer patients significant therapeutic benefits as well as cost efficiency.Angioleiomyoma in a Rare Location
https://practicaldermatology.com/topics/other-dermatology/angioleiomyoma-in-a-rare-location/24012/A minimally invasive treatment is used to treat a tumor in a cosmetically sensitive area.The Skin Microbiome: Commensal Bacteria Impact Human Health
https://practicaldermatology.com/issues/supplements/the-skin-microbiome-commensal-bacteria-impact-human-health/23246/A Long View: Conceptions of Atopic Dermatitis Through the Ages
https://practicaldermatology.com/topics/general-topics/a-long-view-conceptions-of-atopic-dermatitis-through-the-ages/21261/Diverse by Design: The Unique Molecular Footprints of IL-23 Biologics in Psoriasis
https://practicaldermatology.com/issues/april-2024/il23_biologics_in_psoriasis/24457/Christopher Bunick, MD, PhD, discusses a study that explores the structural basis of IL-23 targeted biologic therapies for psoriasis. By mapping the binding sites of these therapies on the IL-23 molecule and correlating molecular properties with clinical efficacy, the study offers insights into whyGLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muDo You Own Real Estate in Your Practice?
https://practicaldermatology.com/topics/practice-management/do-you-own-real-estate-in-your-practice/20783/Five tips for dermatologists considering the sale of real estate to REIT.Skin Reactions: Understanding New Drug Adverse Effects
https://practicaldermatology.com/conferences/aad-summer-2021/skin-reactions-understanding-new-drug-adverse-effects/19975/In addition to needing to stay abreast of new drugs in dermatology, it's important for dermatologists to stay informed about new medications that come to market in general. Vinod Nambudiri, MD, MBA says there are often dermatology-related adverse events that need to be managed. He discusses new cancValeant's Siliq Cleared, AmSpa Survey, New Skin Cancer Imaging
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-s-siliq-cleared-amspa-survey-new-skin-cancer-imaging/18527/The FDA has approved Valeant Pharmaceutical's Siliq (brodalumab) injection for subcutaneous use for patients with moderate-to-severe plaque psoriasis. The American Med Spa Association (AmSpa) has extended the deadline for its comprehensive survey of MedSpas nationwide. Multiphoton microscopy of mitoDermWireTV: Arcutis Takes PASI HD; Galderma at Camp Wonder; Amgen Challenge; LaRoche-Posay Pride
https://practicaldermatology.com/topics/psoriasis/dermwiretv-arcutis-takes-pasi-hd-galderma-at-camp-wonder-amgen-challenge-laroche-posay-pride/19996/The PASI high discrimination or PASI-HD tool was developed by Arcutis Biotherapeutics in collaboration with a panel of psoriasis research experts. Led by Amgen, in partnership with the International Federation of Psoriasis Associations, the Understanding Psoriatic Disease Leveraging Insights for Tre